Dry Eye

Bausch + Lomb announces topline results for phase III trial of NOV03 to treat DED associated with MGD

Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.

Treatment option for dry eye secondary to graft-vs-host disease

Product offers improvement in objective dry eye disease measures, providing relief.

Minocycline shows promise in dry eye trial

Phase 2 trial of 0.3% minocycline microparticle suspension shows promise in dry eye diseases associated with Inflamed meibomian gland dysfunction